Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

August 31, 2002

Conditions
Head and Neck Cancer
Interventions
DRUG

liposomal lurtotecan

Trial Locations (20)

13385

CHU de la Timone, Marseille

21079

Centre de Lutte Contre le Cancer, Georges-Francois Leclerc, Dijon

28041

Hospital Universitario 12 de Octubre, Madrid

44805

CRLCC Nantes - Atlantique, Nantes-Saint Herblain

59020

Centre Oscar Lambret, Lille

63011

Centre Jean Perrin, Clermont-Ferrand

75651

CHU Pitie-Salpetriere, Paris

76038

Centre Henri Becquerel, Rouen

80131

Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples

A-1100

Kaiser Franz Josef Hospital, Vienna (Wien)

B-2650

Universitair Ziekenhuis Antwerpen, Edegem

D-20246

Universitats-Krankenhaus Eppendorf, Hamburg

D-30625

Medizinische Hochschule Hannover, Hanover

00161

Istituti Fisioterapici Ospitalieri - Roma, Rome

1066 CX

Antoni van Leeuwenhoekhuis, Amsterdam

NL-6500 HB

University Medical Center Nijmegen, Nijmegen

1099-023 Codex

Instituto Portugues de Oncologia de Francisco Gentil-Centro de Lisboa, Lisbon

CH-3010

Inselspital, Bern, Bern

CH-1011

Centre Hospitalier Universitaire Vaudois, Lausanne

SW3 6JJ

Royal Marsden NHS Trust, London

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT00022594 - Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer | Biotech Hunter | Biotech Hunter